Home/Pipeline/SmartRD Platform for Biomarker Discovery

SmartRD Platform for Biomarker Discovery

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

NoRD Bio

About NoRD Bio

NoRD Bio is a private, pre-revenue biotech founded in 2020, based in San Diego, CA. The company has developed the SmartRD Platform, a proprietary liquid biopsy and computational platform designed for ultra-deep, multi-omic analysis of cell-free DNA to monitor cancer progression, evolution, and resistance with high sensitivity. Led by a scientifically distinguished team with roots at the Broad Institute, Harvard, and Dana-Farber, NoRD Bio is positioned to address critical gaps in cancer monitoring and biomarker discovery, though it faces significant competition and the challenge of translating its advanced technology into clinical adoption and revenue.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active